The global market for continuous renal replacement therapy (CRRT) was valued at USD 1,356.7 million in 2022, with an expected compound annual growth rate (CAGR) of 8.6% from 2023 to 2030. This growth is driven by several key factors, including the rising incidence of acute kidney injury (AKI), an increasing rate of sepsis, a rapid expansion of hospitals and urgent care centers, and a growing number of hospital admissions. Additionally, constant product launches and innovations from major players in the CRRT space are boosting demand for these treatments. According to the American Kidney Fund, 37 million people in the United States live with kidney disease, and approximately 807,000 are diagnosed with kidney failure, underscoring the critical need for CRRT.

Before the COVID-19 pandemic, around 23,105 patients with AKI required CRRT annually. The pandemic, however, significantly increased the demand for CRRT, as COVID-19-associated AKI reached nearly 4 million cases per year. Among COVID-19 patients, the need for CRRT surged to 4.9%, five times higher than historical rates of 0.9%. In regions across North America, the number of people utilizing CRRT increased by an unprecedented 370% above typical levels. This spike in demand prompted major CRRT providers like Fresenius Medical Care North America to respond rapidly. For instance, in May 2020, Fresenius, through its Renal Therapies Group, released the first batch of multiBic dialysate solutions to U.S. hospitals under FDA emergency use authorization. These solutions were critical in providing CRRT to COVID-19 patients with acute kidney failure.

Gather more insights about the market drivers, restrains and growth of the Continuous Renal Replacement Therapy Market

Product Segmentation Insights:

The CRRT market is segmented into systems and consumables. In 2022, the consumables segment held the largest market share, accounting for 60.6% of total revenue, and is anticipated to grow at the fastest CAGR of 9.1% over the forecast period. Consumables, including charcoal filters, hemofilters, fluids, and other essential components, are widely used in CRRT. Hemofilters, or artificial kidneys, are central to this segment; they use a hollow fiber membrane that determines solute and fluid removal rates. Major players like Baxter and Fresenius offer a broad range of consumables across multiple CRRT modalities, making these products a consistent choice for renal therapy. While consumables are relatively low-cost, they are frequently repurchased due to their essential role in each CRRT session.

During the COVID-19 surge, Baxter International Inc. reported a fivefold increase in demand for various acute dialysis products due to the rise in patients requiring CRRT. In response, Baxter worked with global partners and government entities to address supply issues and increase the availability of consumables like fluids, helping to meet the extraordinary demand in both Europe and the U.S.

The systems segment is expected to grow at a moderate CAGR of 7.8% over the forecast period. CRRT systems are advanced machines designed to provide renal support through blood and fluid pumps, a user-friendly interface, scales, and integrated safety features. Technological advancements in CRRT systems are enhancing treatment precision and reliability. Innovations include high-volume permeability for better fluid control and integration with Electronic Medical Record (EMR) systems, which is likely to boost this segment's growth. Leading manufacturers are developing more sophisticated CRRT devices that ensure safety and efficiency throughout procedures. For example, in May 2021, Baxter International launched the PrisMax 2, an updated version of its next-generation CRRT platform. The PrisMax 2 is tailored to the specific needs of Intensive Care Units (ICUs), facilitating organ support and CRRT while offering simplified interfaces for easy operation.

The continuous innovations and improvements in CRRT systems and consumables underscore the market's commitment to addressing the growing demand for renal replacement therapies, driven largely by the prevalence of chronic and acute kidney conditions and the substantial impact of the COVID-19 pandemic.

Order a free sample PDF of the Continuous Renal Replacement Therapy Market Intelligence Study, published by Grand View Research.